mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2018-1-93-100mrj-815Research ArticleСИМПОЗИУМSYMPOSIUMЗдоровая и полноценная семья пациента с иммуновоспалительным заболеванием: актуальные вопросы и пути их решения. Что может предложить современная медицина?A healthy and nuclear family of a patient with inflammatory disease: topical issues and ways of their solution. What can modern medicine offer?ЛилаА. М.LilaA. M.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

amlila@mail.ruФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation20180204201812193100Copyright © Лила А.М., 20182018Лила А.М.Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/815

Проблема ведения пациентов репродуктивного возраста (прежде всего, женщин) с иммуновоспалительными заболеваниями становится в последнее время все более  актуальной. Ей был посвящен симпозиум, проходивший в рамках Ежегодной научно- практической конференции ФГБНУ НИИР им. В.А. Насоновой «Ранняя стадия ревматических  заболеваний: научные достижения и клиническая практика», на котором выступили  ведущие российские ревматологи, гастроэнтерологи и гинекологи. В рамках симпозиума  было отмечено, что современный уровень развития медицины позволяет многим женщинам  репродуктивного возраста, страдающим ревматическими заболеваниями, воспалительными заболеваниями  кишечника и т. д., благополучно вынашивать и рожать здоровых детей. Достигается это  благодаря эффективному контролю активности болезни, что, в свою очередь, является  результатом как современной эффективной терапевтической тактики, так и доверительного взаимодействия лечащего врача и пациентки.

The problem of managing reproductive-aged patients (primarily women) with inflammatory diseases is becoming more and more relevant in recent years. It was the objective of the symposium held  during the Annual Scientific and Practical Conference of the V.A.  Nasonova Research Institute of Rheumatology on Early-Stage  Rheumatic Diseases: Scientific Advances and Clinical Practice, at  which leading Russian rheumatologists, gastroenterologists and  gynecologists spoke. The Symposium noted that the current level of  development of medicine allows many reproductive-aged women  suffering from rheumatic diseases, inflammatory bowel diseases,  etc. to well bear and give birth to healthy children. This is achieved  due to the effective control of disease activity, which in turn results  from both the current effective therapeutic tactics and the trusting interaction between the attending physician and the female patient.

иммуновоспалительные заболеваниярепродуктивный возрастгенно-инженерные биологические препаратыцертолизумаба пэголimmunoinflammatory diseasesreproductive agebiological agentscertolizumab pegolReferencesDe Man YA, Dolhain RJEM, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum (Arthritis Care Res). 2008;59(9): 1241-8. doi: 10.1002/art.24003De Man YA, Dolhain RJEM, van de Geijn FE, et al. Disease activity of rheumatoid arthritis during pregnancy: results from a nationwide prospective study. Arthritis Rheum (Arthritis Care Res). 2008;59(9): 1241-8. doi: 10.1002/art.24003Meyer O. Making pregnancy safer for patients with lupus. Joint Bone Spine. 2004;71(3):178-82. doi: 10.1016/S1297-319X(03)00155-6Meyer O. Making pregnancy safer for patients with lupus. Joint Bone Spine. 2004;71(3):178-82. doi: 10.1016/S1297-319X(03)00155-6Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248-55. doi: 10.1111/j.1600-0897.1996.tb00172Malek A, Sager R, Kuhn P, et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol. 1996;36(5):248-55. doi: 10.1111/j.1600-0897.1996.tb00172Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-92. doi: 10.1016/j.cgh.2012.11.011Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286-92. doi: 10.1016/j.cgh.2012.11.011Gö testam Skorpen C, Hoeltzenbein M, Tincani A, et al The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;0:1-16. doi: 10.1136/annrheumdis-2015-208840Gö testam Skorpen C, Hoeltzenbein M, Tincani A, et al The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;0:1-16. doi: 10.1136/annrheumdis-2015-208840Mariette X, Fö rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228-33. doi: 10.1136/annrheumdis-2017-212196Mariette X, Fö rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228-33. doi: 10.1136/annrheumdis-2017-212196Clowse MEB, Fö rger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890-6. doi: 10.1136/annrheumdis-2017-211384Clowse MEB, Fö rger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890-6. doi: 10.1136/annrheumdis-2017-211384Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American college of rheumatology reproductive health summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res. 2015;67 (3):313-25. doi: 10.1002/acr.22516Kavanaugh A, Cush JJ, Ahmed MS, et al. Proceedings from the American college of rheumatology reproductive health summit: the management of fertility, pregnancy, and lactation in women with autoimmune and systemic inflammatory diseases. Arthritis Care Res. 2015;67 (3):313-25. doi: 10.1002/acr.22516Van den Brandt S, Zbinden A, Baeten D, et al. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther. 2017;19:64. doi: 10.1186/s13075-017-1269-1Van den Brandt S, Zbinden A, Baeten D, et al. Risk factors for flare and treatment of disease flares during pregnancy in rheumatoid arthritis and axial spondyloarthritis patients. Arthritis Res Ther. 2017;19:64. doi: 10.1186/s13075-017-1269-1Mouyis MA, Thornton CC, Williams D, Giles IP. Pregnancy outcomes in patients with psoriatic arthritis. J Rheumatol. 2017; 44;128-9. doi: 10.3899/jrheum.160929Mouyis MA, Thornton CC, Williams D, Giles IP. Pregnancy outcomes in patients with psoriatic arthritis. J Rheumatol. 2017; 44;128-9. doi: 10.3899/jrheum.160929Polachek A, Li S, Polachek IS, et al. Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. Semin Arthritis Rheum. 2017;46:740-5. doi: 10.1016/j.semarthrit.2017.01.002Polachek A, Li S, Polachek IS, et al. Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. Semin Arthritis Rheum. 2017;46:740-5. doi: 10.1016/j.semarthrit.2017.01.002Ostensen M, Fö rger F. How safe are antirheumatic drugs during pregnancy? Curr Opin Pharmacol. 2013;13(3):470-5. doi: 10.1016/j.coph.2013.03.004Ostensen M, Fö rger F. How safe are antirheumatic drugs during pregnancy? Curr Opin Pharmacol. 2013;13(3):470-5. doi: 10.1016/j.coph.2013.03.004Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Exp Rev Clin Immunol. 2014;9(2):161-74. doi: 10.1586/eci.12.103Ng SW, Mahadevan U. Management of inflammatory bowel disease in pregnancy. Exp Rev Clin Immunol. 2014;9(2):161-74. doi: 10.1586/eci.12.103Roopenian DC, Akilesh Sh. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-25. doi: 10.1038/nri2155Roopenian DC, Akilesh Sh. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007;7:715-25. doi: 10.1038/nri2155Julsgaard M, Nњrgaard M, Hvas CL, et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease. Scand J Gastroenterol. 2014;49(8):958-66. doi: 10.3109/00365521.2014.920913Julsgaard M, Nњrgaard M, Hvas CL, et al. Self-reported adherence to medical treatment, breastfeeding behaviour, and disease activity during the postpartum period in women with Crohn's disease. Scand J Gastroenterol. 2014;49(8):958-66. doi: 10.3109/00365521.2014.920913Hale TW, Hartmann PE. The Transfer of medications into human milk in textbook of human lactation. 2007;Ch. 24:472-4.Hale TW, Hartmann PE. The Transfer of medications into human milk in textbook of human lactation. 2007;Ch. 24:472-4.Hurley WL, Theil PK. Perspectives on Immunoglobulins in Colostrum and Milk. Nutrients. 2011;3(4):442-74. doi:10.3390/nu3040442Hurley WL, Theil PK. Perspectives on Immunoglobulins in Colostrum and Milk. Nutrients. 2011;3(4):442-74. doi:10.3390/nu3040442Zelikin N, Ehrhardt C, Healy AM. Materials and methods for delivery of biological drugs. Nat Chem. 2016:8:997-1007. doi: 10.1038/nchem.2629Zelikin N, Ehrhardt C, Healy AM. Materials and methods for delivery of biological drugs. Nat Chem. 2016:8:997-1007. doi: 10.1038/nchem.2629Бодрягина ЕС, Абдулганиева ДИ, Яхин КК, Одинцова АХ. Сравнительный анализ качества жизни и психологических особенностей пациентов с язвенным колитом и болезнью Крона. Экспериментальная и клиническая гастроэнтерология. 2013;(10):13-9 [Bodyagina ES, Abdulganieva DI, Yakhin KK, Odintsova AH. Comparative analysis of life quality and psychological features of patients with ulcerative colitis and Crohn's disease. Eksperimental'- naya i Klinicheskaya Gastroenterologiya. 2013;(10):13-9 (In Russ.)].Бодрягина ЕС, Абдулганиева ДИ, Яхин КК, Одинцова АХ. Сравнительный анализ качества жизни и психологических особенностей пациентов с язвенным колитом и болезнью Крона. Экспериментальная и клиническая гастроэнтерология. 2013;(10):13-9 [Bodyagina ES, Abdulganieva DI, Yakhin KK, Odintsova AH. Comparative analysis of life quality and psychological features of patients with ulcerative colitis and Crohn's disease. Eksperimental'- naya i Klinicheskaya Gastroenterologiya. 2013;(10):13-9 (In Russ.)].Ostensen M. Rheumatoid arthritis: The effect of RA and medication on female fertility. Nat Rev Rheumatol. 2014;10:518-9. doi: 10.1038/nrrheum.2014.113Ostensen M. Rheumatoid arthritis: The effect of RA and medication on female fertility. Nat Rev Rheumatol. 2014;10:518-9. doi: 10.1038/nrrheum.2014.113Ban L, Tata LJ, Humes DJ, et al. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther. 2015;42(7): 855-66. doi: 10.1111/apt.13354Ban L, Tata LJ, Humes DJ, et al. Decreased fertility rates in 9639 women diagnosed with inflammatory bowel disease: a United Kingdom population-based cohort study. Aliment Pharmacol Ther. 2015;42(7): 855-66. doi: 10.1111/apt.13354Mills B, Dao Kh, Tecson K, et al. Perceptions and outcomes of pregnancy and lactation in patients with rheumatic diseases. ACR 2017. Abstract Number 355.Mills B, Dao Kh, Tecson K, et al. Perceptions and outcomes of pregnancy and lactation in patients with rheumatic diseases. ACR 2017. Abstract Number 355.Brö ms G, Granath F, Ekbom A, et al. Low risk of birth defects for infants whose mothers are treated with anti-Tumor Necrosis Factor agents during pregnancy. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):234-41. doi: 10.1016/j.cgh.2015.08.039Brö ms G, Granath F, Ekbom A, et al. Low risk of birth defects for infants whose mothers are treated with anti-Tumor Necrosis Factor agents during pregnancy. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):234-41. doi: 10.1016/j.cgh.2015.08.039Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(4):395-9. doi: 10.1097/01.MIB.0000164023.10848.c4Mahadevan U, Terdiman JP, Aron J, et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(4):395-9. doi: 10.1097/01.MIB.0000164023.10848.c4D'Hauterive SP, Kesseler S, Ruggeri P, et al. Certolizumab pegol treatment does not result in a decrease in semen quality: results from a phase 1 study. EULAR 2012; Poster FRI0160.D'Hauterive SP, Kesseler S, Ruggeri P, et al. Certolizumab pegol treatment does not result in a decrease in semen quality: results from a phase 1 study. EULAR 2012; Poster FRI0160.Abhyankar A, Ham M, Moss AS. Metaanalysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):460-6. doi: 10.1111/apt.12417Abhyankar A, Ham M, Moss AS. Metaanalysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(5):460-6. doi: 10.1111/apt.12417Olsen K∅, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002 Jan;122(1):15-9. doi: 10.1053/gast.2002.30345Olsen K∅, Juul S, Berndtsson I, et al. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology. 2002 Jan;122(1):15-9. doi: 10.1053/gast.2002.30345Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58(2):229-37. doi: 10.1016/S0020-7292(97)00088-XHudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease. Int J Gynaecol Obstet. 1997;58(2):229-37. doi: 10.1016/S0020-7292(97)00088-XVan der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced- based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn's Colitis. 2015;107-124. doi: 10.1093/ecco-jcc/jju006Van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced- based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohn's Colitis. 2015;107-124. doi: 10.1093/ecco-jcc/jju006Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3): 734-57.e1. doi: 10.1053/j.gastro.2015.12.003Nguyen GC, Seow CH, Maxwell C, et al. The Toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3): 734-57.e1. doi: 10.1053/j.gastro.2015.12.003Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut. 2003;52(2):159-61. doi: 10.1136/gut.52.2.159.Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut. 2003;52(2):159-61. doi: 10.1136/gut.52.2.159.Mor G, Ingrid Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011;1221:80-7. doi: 10.1111/j.1749-6632.2010.05938.xMor G, Ingrid Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci. 2011;1221:80-7. doi: 10.1111/j.1749-6632.2010.05938.xO'Toole A, Nwanne O, Tomlinson T. Inflammatory Bowel Disease Increases Risk of Adverse Pregnancy Outcomes: A Meta- Analysis. Dig Dis Sci. 2015;60(9):2750-61. doi: 10.1007/s10620-015-3677-xO'Toole A, Nwanne O, Tomlinson T. Inflammatory Bowel Disease Increases Risk of Adverse Pregnancy Outcomes: A Meta- Analysis. Dig Dis Sci. 2015;60(9):2750-61. doi: 10.1007/s10620-015-3677-xPalmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi: 10.1155/2012/985646. Epub 2011 Oct 1.Palmeira P, Quinello C, Silveira-Lessa AL, et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646. doi: 10.1155/2012/985646. Epub 2011 Oct 1.

The authors declare that there are no conflicts of interest present.